Overview

  • Product nameAnti-Met (c-Met) antibodySee all Met (c-Met) primary antibodies ...
  • Description
    Goat polyclonal to Met (c-Met)
  • Tested applicationsICC/IF, Neutralising, ELISA, WB more details
  • Species reactivity
    Reacts with: Mouse, Human
  • Immunogen

    Recombinant fragment (extracellular domain)(Human).

  • General notes


    The detection limit in immunoblotting for recombinant human HGF R is approximately 5 ng/lane under non-reducing and reducing conditions. Both the alpha and beta chains of HGF R are detected by this antibody under reducing conditions. The detection limit in ELISA for recombinant human HGF R is approximately 0.16 ng/well.

Properties

Applications

Our Abpromise guarantee covers the use of ab10728 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Notes
ICC/IF Use at an assay dependent concentration.
Neutralising Use a concentration of 0.5 - 2 µg/ml. ab10728 has the ability to neutralize receptor-ligand interaction. Approximately 0.5-2 mg/mL of the antibody will block 50% of the binding of recombinant human HGF (5 ng/mL) to immobilized recombinant human HGF R/Fc Chimera (100 mL of a 1 mg/mL solution coated in each well) in an ELISA. 10 mg/mL of the antibody will block 90% of binding.
ELISA Use a concentration of 0.5 - 1 µg/ml.
WB Use a concentration of 0.1 - 0.2 µg/ml. Predicted molecular weight: 129 kDa.

Target

  • FunctionReceptor for hepatocyte growth factor and scatter factor. Has a tyrosine-protein kinase activity. Functions in cell proliferation, scattering, morphogenesis and survival.
  • Involvement in diseaseNote=Activation of MET after rearrangement with the TPR gene produces an oncogenic protein.
    Note=Defects in MET may be associated with gastric cancer.
    Defects in MET are a cause of hepatocellular carcinoma (HCC) [MIM:114550].
    Defects in MET are a cause of renal cell carcinoma papillary (RCCP) [MIM:605074]. It is a subtype of renal cell carcinoma tending to show a tubulo-papillary architecture formed by numerous, irregular, finger-like projections of connective tissue. Renal cell carcinoma is a heterogeneous group of sporadic or hereditary carcinoma derived from cells of the proximal renal tubular epithelium. It is subclassified into common renal cell carcinoma (clear cell, non-papillary carcinoma), papillary renal cell carcinoma, chromophobe renal cell carcinoma, collecting duct carcinoma with medullary carcinoma of the kidney, and unclassified renal cell carcinoma.
    Note=A common allele in the promoter region of the MET shows genetic association with susceptibility to autism in some families. Functional assays indicate a decrease in MET promoter activity and altered binding of specific transcription factor complexes.
    Note=MET activating mutations may be involved in the development of a highly malignant, metastatic syndrome known as cancer of unknown primary origin (CUP) or primary occult malignancy. Systemic neoplastic spread is generally a late event in cancer progression. However, in some instances, distant dissemination arises at a very early stage, so that metastases reach clinical relevance before primary lesions. Sometimes, the primary lesions cannot be identified in spite of the progresses in the diagnosis of malignancies.
  • Sequence similaritiesBelongs to the protein kinase superfamily. Tyr protein kinase family.
    Contains 3 IPT/TIG domains.
    Contains 1 protein kinase domain.
    Contains 1 Sema domain.
  • DomainThe kinase domain is involved in SPSB1 binding.
  • Post-translational
    modifications
    Dephosphorylated by PTPRJ at Tyr-1349 and Tyr-1365.
  • Cellular localizationMembrane.
  • Target information above from: UniProt accession P08581 The UniProt Consortium
    The Universal Protein Resource (UniProt) in 2010
    Nucleic Acids Res. 38:D142-D148 (2010) .

    Information by UniProt
  • Database links
  • Alternative names
    • AUTS9 antibody
    • c met antibody
    • c met antibody
    • cmet antibody
    • cmet antibody
    • D249 antibody
    • Hepatocyte growth factor receptor antibody
    • Hepatocyte growth factor receptor Precursor antibody
    • Hepatocyte growth factor receptor Precursor antibody
    • HGF antibody
    • HGF receptor antibody
    • HGF receptor antibody
    • HGF SF receptor antibody
    • HGF SF receptor antibody
    • HGF/SF receptor antibody
    • HGFR antibody
    • MET antibody
    • Met proto oncogene tyrosine kinase antibody
    • Met proto oncogene tyrosine kinase antibody
    • Met proto-oncogene (hepatocyte growth factor receptor) antibody
    • Met proto-oncogene antibody
    • Met protooncogene antibody
    • MET_HUMAN antibody
    • Oncogene MET antibody
    • Oncogene MET antibody
    • Par4 antibody
    • Proto-oncogene c-Met antibody
    • RCCP2 antibody
    • Renal cell carcinoma papillary 2 gene antibody
    • Renal cell carcinoma papillary 2 gene antibody
    • Scatter factor receptor antibody
    • SF receptor antibody
    • Tyrosine-protein kinase Met antibody
    see all

Anti-Met (c-Met) antibody images

  • ab10728 staining mouse muscle cells by ICC/IF.  Cells were PFA fixed and permeabilized in 0.5% Triton prior to blocking with 1% serum for 30 minutes at 25°C.  The primary antibody was diluted 1/50 and incubated with the sample for 1 hour at 25°C.  An Alexa Fluor® 488 conjugated chicken anti-goat antibody was used as the secondary.

    See Abreview

References for Anti-Met (c-Met) antibody (ab10728)

This product has been referenced in:
  • Yan K  et al. MicroRNA-34a Inhibits the Proliferation and Metastasis of Osteosarcoma Cells Both In Vitro and In Vivo. PLoS One 7:e33778 (2012). WB ; Mouse . Read more (PubMed: 22457788) »

See 1 Publication for this product

Product Wall

Thank you for contacting us.


I contacted the lab and regrettably I can confirm, that this antibody has to our knowledge not been tested in vivo in nude mice or any other mice. For this reason we con not provide any related data. I am sorr...

Read More

Thank you for confirming these details and for your cooperation. The details provided enable us to closely monitor the quality of our products.

I am sorry the products did not perform as stated on the datasheet and for the inconvenience this...

Read More

Thank you for taking the time to complete our questionnaire.

The details you have kindly provided will provide us with vital information for our monitoring of product quality.

I appreciate the time the customer have spent in the l...

Read More

Thank you for taking the time to contact us. I am sorry to hear you have had difficulty obtaining satisfactory results from this antibody.

I would like to reassure you that our antibody are tested and covered by our 6 month guarantee for the...

Read More

Thank you for your reply. Because we carry over 70,000 products, it isn't feasible for us to keep small sample sizes of our products.

If the product is to be used in an untested species or application, you may be eligible for our testing dis...

Read More

Thank you for your inquiry.

This antibody can be used to neutralise the c-Met:HGF interaction - At 0.5-2 μg/mL the antibody will block 50% of the binding of 5 ng/mL recombinant human HGF to 0.1 μg immobilized recombinant human HGF R/c-M...

Read More
Application Immunocytochemistry/ Immunofluorescence
Sample Mouse Cell (muscle cells)
Specification muscle cells
Fixative Paraformaldehyde
Permeabilization Yes - 0.5% Triton
Blocking step Serum as blocking agent for 30 minute(s) · Concentration: 1% · Temperature: 25°C
Username

Abcam user community

Verified customer

Submitted Nov 01 2007

Thank you for your enquiry. For ab10728, the immunogen was from the extracellular domain. It was not tested against a cell line. The neutralization assay is described as follows. Neutralization of Receptor-Ligand Interaction: Approximately 0.3-1.0 ...

Read More

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"